Sodium-glucose co-transporter-2 (SGLT2) inhibitors reduce heart failure hospitalisations by more than a third and halve all-cause mortality compared to other glucose-lowering treatments in type 2 diabetes, according to new research presented at the American College of Cardiology’s meeting in Washington.

Sponsor AstraZeneca says the study is “the first large real-world evidence study of its kind” comparing SGLT-2 inhibitors and other type 2 diabetes medicines.

The study used databases from six countries (the US, Norway, Denmark, Sweden, Germany and the UK) to match 154,523 type 2 diabetes patients taking SGLT-2 inhibitors (dapagliflozin, canagliflozin, empagliflozin) with the same number of controls taking other glucose-lowering drugs.

Most patients (87 per cent) did not have a history of cardiovascular disease. There were 961 hospitalisations for heart failure across the six countries. The German database did not yield linked mortality but in the remaining five countries, 1,334 of 215,622 patients died.

Treatment with a SGLT-2 inhibitor reduced hospital-isations for heart failure by 39 per cent (hazard ratio [HR] 0.61) and deaths from any cause by 51 per cent (HR 0.49) compared with other type 2 diabetes medicines. SGLT-2 inhibitors reduced the composite of heart failure hospitalisation or death from any cause by 46 per cent. There was no significant difference by country.

The study did not examine other cardiovascular events, such as myocardial infarction and stroke, or focus on safety. Moreover, the authors also note that experience with SGLT-2 inhibitors “in real-world practice is still relatively short”. Longer-term follow-up is therefore needed to determine whether the benefits are sustained.

Recommended

Inhaled corticosteroids increase the risk of pneumonia

Inhaled corticosteroid use could be linked to pneumonia, according to a Canadian study

Extend MURs and NMS in young people?

There is scope to extend NMS reviews and MURs in children, young people and their carers, new research suggests

Popular

Leg & foot care: Best foot forward

Feet are usually shoved in shoes and ignored but paying them a bit of attention can make a big difference

Watching Briefs: Leg & foot care

The latest OTC product news and campaigns in the leg & foot care category rounded up here

Watching Briefs: Pain management

The latest product news rounded up in pharmacy's pain management category